Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 5,701–5,800 of 15,747
Rectifying COVID-19 disparities with treatment and vaccination
Carethers, J. M. (2021) · JCI Insight · doi:10.1172/jci.insight.147800 · Cited by 16
Deng, S., Shao, H., Shang, H., Pang, L., Chen, X., Cao, J., Wang, Y., & Zhao, Z. (2024) · Vaccines · doi:10.3390/vaccines13010025 · Cited by 15
“Lipid nanoparticles (LNPs) have emerged as the most advanced drug delivery platforms and attracted extensive attention in mRNA delivery, particularly during the COVID-19 pandemic [3,4].”
Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment
Zou, H., Yang, Y., Dai, H., Xiong, Y., Wang, J., Lin, L., & Chen, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.732403 · Cited by 16
First Case of Erythema Nodosum Associated With Pfizer Vaccine
Aly, M. H., Alshehri, A. A., Mohammed, A., et al. (2021) · Cureus · doi:10.7759/cureus.19529 · Cited by 15
“Other local adverse effects were reported such as pain at the site of injection, redness, and swelling [5].”
BackgroundRNA Engineering for Public Health: Innovations in RNA-Based Diagnostics and Therapeutics
Thavarajah, W., Hertz, L. M., Bushhouse, D. Z., Archuleta, C. M., & Lucks, J. B. (2021) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-101420-014055 · Cited by 19
“…et al. 2020) Mass vaccination efforts against Covid-19; early data show multiple vaccines safe, effective (Baden et al. 2021, Dagan et al. 2021, Polack et al. 2020) Engineered RNA circuits combined with protein biosensors for low-cost water tests (Jung et al. 2020) Moderna (2020) SARS-CoV-2…”
BackgroundBiologics for Psoriasis During the COVID-19 Pandemic
Zeng, H., Wang, S., Chen, L., & Shen, Z. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.759568 · Cited by 17
Su, W.-Y., Du, P.-X., Santos, H. M., Ho, T.-S., Keskin, B. B., Pau, C. H., Yang, A.-M., Chou, Y.-Y., Shih, H.-C., & Syu, G. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c05567 · Cited by 14
Tear antibodies to SARS‐CoV‐2: implications for transmission
Selva, K. J., Davis, S. K., Haycroft, E. R., Lee, W. S., López, E., Reynaldi, A., Davenport, M. P., Kent, H. E., Juno, J. A., Chung, A. W., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1354 · Cited by 15
Lan, Z., Yan, J., Yang, Y., Tang, Z., Guo, X., Wu, Z., & Jin, Q. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-05216-5 · Cited by 16
A Modeling Study on Vaccination and Spread of SARS-CoV-2 Variants in Italy
Antonini, C., Calandrini, S., & Bianconi, F. (2021) · Vaccines · doi:10.3390/vaccines9080915 · Cited by 15
“1% efficacy at preventing COVID-19 illness, respectively [11,12].”
BackgroundSkarzynska, M. B., Matusiak, M., & Skarzynski, P. H. (2022) · Audiology Research · doi:10.3390/audiolres12030025 · Cited by 15
“Both study sponsors will continue to follow the safety and efficacy of the vaccine for the next 2 years [69,70].”
BackgroundGuijarro, C., Galán, I., Martínez-Ponce, D., Pérez‐Fernández, E., Goyanes, M. J., Castilla, V., & Velasco, M. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.06.026 · Cited by 15
The Risk of Autoimmunity Development following mRNA COVID-19 Vaccination
Świerkot, J., Madej, M., Szmyrka−Kaczmarek, M., Korman, L., Sokolik, R., Andrasiak, I., Morgiel, E., & Sebastian, A. (2022) · Viruses · doi:10.3390/v14122655 · Cited by 16
Protocol of safe vaccination against COVID‐19 in patients with high risk of allergic reactions
Romantowski, J., Kruszewski, J., Solarski, O., Bant, A., Chciałowski, A., Pietrzyk, I., Sańpruch, P., Górska, A., Chełmińska, M., Knurowska, A., et al. (2022) · Clinical and Translational Allergy · doi:10.1002/clt2.12152 · Cited by 14
Igawa, G., Ai, T., Yamamoto, T. S., Ito, K., Nojiri, S., Saito, K., Wakita, M., Fukuda, H., Hori, S., Misawa, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-12809-x · Cited by 16
“This study has several limitations: (1) the present study was conducted in a single university hospital; (2) participants were HCWs who are relatively healthy and predominantly younger, and approximately 75% of the two youngest groups combined (20–30 s) were women; (3) chronological changes in antibody titers could no…”
ResultStrong, C., Leung, J., Kang, E., Badior, K. E., Robertson, M. K., Pereyra, N., Rowe, E. M., Wietrzny, A., Ma, B., Noronha, Z., et al. (2024) · Blood · doi:10.1182/blood.2024024405 · Cited by 19
Structure-Guided Development of Bivalent Aptamers Blocking SARS-CoV-2 Infection
Rahman, M. S., Han, M. J., Kim, S. W., Kang, S. M., Kim, B. R., Kim, H., Lee, C. J., Noh, J. E., Kim, H., Lee, J., et al. (2023) · Molecules · doi:10.3390/molecules28124645 · Cited by 18
Effectiveness of COVID-19 Vaccines in Patients Under Maintenance Hemodialysis
Mahallawi, W. H., Ibrahim, N. A., & Mumena, W. A. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s345686 · Cited by 14
“The first is an mRNA-based vaccine, a lipid nanoparticlecapture that encodes perfusion-stabilized full-length spike proteins.(22) The latter is a vector vaccine that uses the full-length codon for the S-protein.”
BackgroundCOVID-19 Vaccine Could Trigger the Relapse of Secondary Hypersomnia
Wu, M., Li, S. X., Xue, P., Zhou, J., & Tang, X. (2021) · Nature and Science of Sleep · doi:10.2147/nss.s345801 · Cited by 15
“A multinational randomized controlled trial has confirmed that a two-dose regimen of BNT162b2 mRNA could result in 95% protection against COVID-19 in individuals aged 16 years or above.(11) However, as for anything biologically active, the vaccine may carry potential risks of causing adverse Correspondence: Junying Zh…”
BackgroundInfluentialSerious harms of the COVID-19 vaccines: a systematic reviewPreprint
Gøtzsche, P. C., & Demasi, M. (2022) · medRxiv · doi:10.1101/2022.12.06.22283145 · Cited by 19
Vaccinating People with Obesity for COVID-19: EASO Call for Action
Dicker, D., Golan, R., Baker, J. L., et al. (2021) · Obesity Facts · doi:10.1159/000516524 · Cited by 15
Immune Thrombocytopenic Purpura Following Pfizer-BioNTech COVID-19 Vaccine in an Elderly Female
Jasaraj, R. B., Shrestha, D. B., Gaire, S., & Kassem, M. A. (2021) · Cureus · doi:10.7759/cureus.16871 · Cited by 15
“All other adverse effects were mild [5].”
Mucosal vaccines for viral diseases: Status and prospects
Ma, B., Tao, M., Li, Z., Zheng, Q., Haigang, W., & Chen, P. (2024) · Virology · doi:10.1016/j.virol.2024.110026 · Cited by 17
Bozkurt, B., Das, S. R., Addison, D., Gupta, A., Jneid, H. M., Khan, S. S., Koromia, G. A., Kulkarni, P. A., LaPoint, K., Lewis, E. F., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.03.355 · Cited by 19
ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises
Maguire, D., McLaren, D. S., Rasool, I., Shah, P. M., Lynch, J. M., & Murray, R. D. (2021) · Clinical Endocrinology · doi:10.1111/cen.14566 · Cited by 16
Matsuura, T., Fukushima, W., Nakagama, Y., Kido, Y., Kase, T., Kondo, K., Kaku, N., Matsumoto, K., Suita, A., Komiya, E., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.018 · Cited by 15
“Introduction Messenger RNA vaccines use a novel technology [1], and have been shown to have a high level of efficacy against coronavirus disease (COVID-19) in pre-licensure phase 3 clinical trials [2, 3].”
BackgroundWu, S., Yang, Y., Lian, X., Zhang, F., Hu, C., Tsien, J., Chen, Z., Sun, Y., Vaidya, A., Kim, M., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c13154 · Cited by 15
Advances in vaccine development for Chlamydia trachomatis
Poston, T. B. (2024) · Pathogens and Disease · doi:10.1093/femspd/ftae017 · Cited by 23
“Both were the first mRNA vaccines licensed for humans and generated both neutralizing antibodies and Th1-biased responses (Polack et al. 2020 , Baden et al. 2021 ).”
BackgroundAjaimy, M., Liriano-Ward, L. E., Graham, J. A., & Akalin, E. (2021) · Kidney360 · doi:10.34067/kid.0002532021 · Cited by 15
Tapescu, I., Madsen, P. J., Lowenstein, P. R., Castro, M. G., Bagley, S. J., Fan, Y., & Brem, S. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1454370 · Cited by 18
Better, Faster, Stronger: Accelerating mRNA ‐Based Immunotherapies With Nanocarriers
Carvalho, H., Fidalgo, T. A. S., Acúrcio, R. C., Matos, A. I., Satchi‐Fainaro, R., & Florindo, H. F. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.2017 · Cited by 19
New vector and vaccine platforms: mRNA, DNA, viral vectors
Hanke, T. (2022) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000763 · Cited by 18
“Initial obstacles of instability, inefficient delivery, activation of innate immunity through intracellular RNA sensors and large-scale manufacturing have been overcome sufficiently to allowModerna’s mRNA-1273 and BioNTech/Pfizer’s BNT162b2 vaccines to emerge during the COVID-19 pandemic as well tolerated and efficaci…”
BackgroundMehla, R., Kokate, P., Bhosale, S. R., Vaidya, V., Narayanan, S., Shandil, R. K., Singh, M., Rudramurthy, G. R., Naveenkumar, C. N., Bharathkumar, K., et al. (2023) · Vaccines · doi:10.3390/vaccines11020255 · Cited by 17
Català, M., Burn, E., Rathod‐Mistry, T., Xie, J., Delmestri, A., Prieto‐Alhambra, D., & Jödicke, A. M. (2023) · International Journal of Epidemiology · doi:10.1093/ije/dyad138 · Cited by 17
PUS1 is a novel biomarker for predicting poor outcomes and triple-negative status in breast cancer
Fang, Z., Shen, H.-Y., Xu, Q., Zhou, H., Li, L., Yang, S.-Y., Zhu, Z. Y., & Tang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1030571 · Cited by 14
“However , i ts functions have been underappreciated for a long time until the recent discovery that it greatly contributes to efficacy of the mRNA COVID-19 Vaccines (14, 15).”
BackgroundGuo, X., Liu, D., Huang, Y., Deng, Y., Wang, Y., Mao, J., Zhou, Y., Xiong, Y., & Gao, X. (2023) · Virology Journal · doi:10.1186/s12985-023-02023-0 · Cited by 20
“Based on the recent rapid development of COVID-19 mRNA vaccines and their remarkable efficacy in clinical applications [14], driving the development of the entire mRNA vaccine industry, this paper reviews existing mRNA vaccines with potential clinical applications for the treatment of viral diseases.”
BackgroundHoffmann, M., Gerlach, S., Hoffmann, C., Richter, N., Hersch, N., Csiszár, Á., Merkel, R., & Hoffmann, B. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1066887 · Cited by 16
“, 2018), nucleic acid therapies can also be successfully used for immunization, as demonstrated in the current Covid pandemic via a SARS-CoV2 mRNA vaccine (Chung et al., 2020; Polack et al., 2020).”
MethodDan, J. M., Antunes, R. D. S., Grifoni, A., Weiskopf, D., Crotty, S., & Sette, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac310 · Cited by 17
Niessen, F. A., Knol, M. J., Hahné, S. J. M., Bonten, M. J. M., & Bruijning-Verhagen, P. C. J. L. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.011 · Cited by 15
Ferreira, C. D. S., Dantés, H. G., Bellei, N., López, E. L., Crespo, K. A. N., O’Ryan, M., & Villegas, J. (2021) · Viruses · doi:10.3390/v13122391 · Cited by 18
“…that infection remains possible in fully vaccinated individuals, despite high effectiveness against more severe forms of the disease (such as those causing hospitalization or death) as reported by COVID-19 vaccine clinical trials and real-world evidence from vaccine rollout programs [76,184–194].”
ResultCircRNA: Unlocking new frontiers in therapeutic and vaccine development
Bahrulolum, H., Rouzbahani, F. N., Hoseini, Z. S., Chaharmahali, M., & Hosseini, S. M. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.038 · Cited by 20
Understanding and Dealing the SARS-CoV-2 Infection: An Updated Concise Review
Hossain, M. J., Kuddus, M. R., Rashid, M. A., & Sultan, M. Z. (2021) · Bangladesh Pharmaceutical Journal · doi:10.3329/bpj.v24i1.51637 · Cited by 16
Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes
Woodworth, K. E., Callaghan, N. I., & Huyer, L. D. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202508761 · Cited by 20
Post COVID-19 vaccine deaths - Singapore’s early experience
Yeo, A., Kuek, B., Mandy, L. A. U., Tan, S. R., & Chan, S. (2022) · Forensic Science International · doi:10.1016/j.forsciint.2022.111199 · Cited by 18
Stroke After SARS-CoV-2 mRNA Vaccine: A Nationwide Registry Study
Ihle‐Hansen, H., Bøås, H., Tapia, G., Hagberg, G., Ihle‐Hansen, H., Berild, J. D., Selmer, R. M., Karlstad, Ø., Gulseth, H. L., & Ariansen, I. (2023) · Stroke · doi:10.1161/strokeaha.122.040430 · Cited by 17
Advances of Nanotechnology Toward Vaccine Development Against Animal Infectious Diseases
Wang, X., Gao, X., Wang, L., Lin, J., & Liu, Y. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202305061 · Cited by 19
Corosolic acid derivative-based lipid nanoparticles for efficient RNA delivery
Liu, Y., Zhang, R., Yang, Y., Liu, X., & Jiang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.073 · Cited by 16
Reactivation of Herpes Zoster Virus After COVID-19 Vaccination: Is There Any Association?
Agrawal, S., Verma, K., Verma, I., & Gandhi, J. (2022) · Cureus · doi:10.7759/cureus.25195 · Cited by 18
“Side effects of COVID-19 vaccines have been mostly mild to moderate, including fever, fatigue, body ache, headache, chills, muscle pain, diarrhea, and skin rashes [3].”
BackgroundGuo, C. M., Chai, X., Baerlike, M., Liu, Y., Wang, Y., Shao, F., Huang, Q., Zhang, W., Cen, S., Dong, Y., et al. (2024) · hLife · doi:10.1016/j.hlife.2024.09.002 · Cited by 17
Strategic Collaboration and Partnerships in R&D for Innovation
Subrahmanyam, S. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-0812-8.ch010 · Cited by 16
Méndez-García, A., García-Mendoza, M. A., Zárate-Peralta, C. P., Flores-Pérez, F. V., Carmona-Ramirez, L. F., Pathak, S., Banerjee, A., Duttaroy, A. K., & Paul, S. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1555563 · Cited by 22
Gümüşburun, R., Dalgıç, C. T., Mete, N., & Sin, A. Z. (2022) · International Archives of Allergy and Immunology · doi:10.1159/000524099 · Cited by 16
Effects of worldwide interventions and vaccination on COVID-19 between waves and countriesPreprint
Ge, Y., Zhang, W., Liu, H., Ruktanonchai, C. W., Hu, M., Wu, X., Song, Y., Ruktanonchai, N., Yan, W., Feng, L., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-396989/v1 · Cited by 16
Christensen, B., Laydon, D. J., Chełkowski, T., Jemielniak, D., Vollmer, M., Bhatt, S., & Krawczyk, K. (2022) · JMIR Infodemiology · doi:10.2196/35121 · Cited by 21
Yamaguchi, C., Kunikata, H., Hashimoto, K., et al. (2022) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2022.101616 · Cited by 15
“19 In this case, although the patient had a mild reaction after the first dose, we consider that the second dose triggered an immune mechanism.”
Shahrear, S., & Islam, A. B. M. M. K. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.105098 · Cited by 17
Pradenas, E., Marfil, S., Urrea, V., Trigueros, M., Pidkova, T., Pons-Grífols, A., Ortiz, R., Rovirosa, C., Tarrés-Freixas, F., Aguilar‐Gurrieri, C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106457 · Cited by 17
“Time between the first plasma sample collection and the indicated event (median days [IQR]): Last vaccine dose 34 [32-38] 34 [14-46] 34 [31-37] 33 [31-41] 90 [60-92] 35 [32-70] Pre-vaccine infection NA 336 [153-360] NA 588 [459-662] NA 621 [424-677] Post-vaccine infection NA NA NA NA 35 [18-43] 25 [13-38] Time between…”
Tolerogenic Nano-/Microparticle Vaccines for Immunotherapy
Liu, Q., Chen, G., Liu, X., Tao, L., Fan, Y., & Xia, T. (2024) · ACS Nano · doi:10.1021/acsnano.3c11647 · Cited by 31
Targeting cardiac fibrosis with Chimeric Antigen Receptor-Engineered Cells
Zhang, Q., Dai, J., Liu, T., Rao, W., Li, D., Gu, Z., Huang, L., Wang, J., & Hou, X. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05134-6 · Cited by 15
“Lipid nanoparticle (LNP)-encapsulated mRNA has been recognised worldwide for its efficacy in the treatment of COVID-19 [108, 109].”
Recurrence of Myopericarditis Following mRNA COVID-19 Vaccination in a Male Adolescent
Umei, T. C., Kishino, Y., Watanabe, K. S., Shiraishi, Y., Inohara, T., Yuasa, S., & Fukuda, K. (2021) · CJC Open · doi:10.1016/j.cjco.2021.12.002 · Cited by 15
“Vaccination against SARS-CoV-2 is considered a protective approach, with more than 95% efficacy, to control the COVID-19 pandemic.(1) However, some cases of myopericarditis have been reported recently as complications of mRNA COVID-19 vaccination with an incidence of 1 case per 10,000e100,000 inoculations.”
BackgroundNucleic acid vaccines and CpG oligodeoxynucleotides for allergen immunotherapy
Jacquet, A. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000772 · Cited by 15
Delivering the message: How a novel technology enabled the rapid development of effective vaccines
Shapiro, L., & Losick, R. M. (2021) · Cell · doi:10.1016/j.cell.2021.08.019 · Cited by 15
“BioNTech and Pfizer optimized a modified mRNA-lipid nano particle vaccine against the SARS-CoV-2 spike protein that triggered strong production of neutralizing antibodies.”
MethodInfluentialSasanami, M., Kayano, T., & Nishiura, H. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022126 · Cited by 15
Johnson, K. D., Akingbola, O., Anderson, J., Hart, J., Chapple, A. G., Woods, C., Yeary, K. H. K., & McLean, A. (2021) · Health Promotion Perspectives · doi:10.34172/hpp.2021.22 · Cited by 19
Rabaan, A. A., Bakhrebah, M. A., Mutair, A. S. A., Alhumaid, S., Al-Jishi, J. M., AlSihati, J., Albayat, H., Alsheheri, A., Aljeldah, M. M., Garout, M. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10070985 · Cited by 16
“The COVID-19 vaccines developed by the Pfizer and Moderna relies on the use of a combination of mRNA and nanoparticles for the efficient delivery of vaccines [104,105].”
BackgroundPeled, Y., Afek, A. B., Kreiss, Y., Rahav, G., Nemet, I., Kliker, L., Indenbaum, V., Ram, E., Lavee, J., Segev, A., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.05.014 · Cited by 16
Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease
Kastl, A., Weaver, K. N., Zhang, X., Strople, J. A., Adler, J., Dubinsky, M. C., Bousvaros, A., Watkins, R. D., Dai, X., Chen, W., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002016 · Cited by 15
Doneddu, P. E., Spina, E., Briani, C., Fabrizi, G. M., Manganelli, F., & Nobile‐Orazio, E. (2021) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12435 · Cited by 16
Edwards, K. R., Malhi, H., Schmidt, K., Davis, A. R., Homad, L. J., Warner, N. L., Chhan, C. B., Scharffenberger, S. C., Gaffney, K., Hinkley, T. C., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00907-y · Cited by 17
Bock, H. L., Juretzek, T., Handreka, R., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103554 · Cited by 15
“In the ongoing Covid-19 pandemic vaccination is considered the most effective measure to provide both: a significant public health benefit by slowing the spread of the virus, as well as conferring an excellent personal protection against severe COVID-19.(1, 2) While there is no evidence to suggest that SARS CoV-2 vacc…”
Plüß, M., Mitteldorf, C., Szuszies, C. J., & Tampe, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.868133 · Cited by 15
“As the coronavirus pandemic is ongoing and new variants of SARS-CoV-2 emerge, there is an urgent need for vaccines to protect individuals at high risk for complications and to potentially control disease outbreaks by herd immunity (1, 2).”
BackgroundLonze, B. E., Spiegler, P. A., Wesson, R., Alachkar, N., Petkova, E., Weldon, E. P., Dieter, R. A., Li, Y., Quinn, M. M., Mattoo, A., et al. (2022) · Critical Care Medicine · doi:10.1097/ccm.0000000000005591 · Cited by 18
Evaluating the Long-Term Efficacy of COVID-19 Vaccines
(2021) · doi:10.1101/2021.01.13.21249779 · Cited by 15
Ong, A. K. S., Prasetyo, Y. T., Lagura, F. C., Ramos, R. N., Salazar, J. M. L., Sigua, K. M., Villas, J. A., Chuenyindee, T., Nadlifatin, R., Persada, S. F., et al. (2022) · Public Health in Practice · doi:10.1016/j.puhip.2022.100300 · Cited by 15
(2021) · doi:10.1101/2021.07.02.21259913 · Cited by 15
“In the absence of validated correlates of vaccine-induced protection against SARS-Cov-2, we reasoned that MHD patients would have the same level of protection than the general population (17) if they were able to generate similar titers of anti-spike receptor binding domain (RBD) IgG.”
BackgroundResultInfluentialDermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of Concern
McMillan, C. L. D., Azuar, A., Choo, J. J. Y., Modhiran, N., Amarilla, A. A., Isaacs, A., Honeyman, K. E., Cheung, S. T. M., Liang, B., Wurm, M. J., et al. (2022) · Vaccines · doi:10.3390/vaccines10040578 · Cited by 15
Standards of Care in Diabetes. The position of Diabetes Poland – 2024
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Broncel, M., Budzynski, A. Z., Cyganek, K., Cypryk, K., CYRANKA, K. M., Czupryniak, L., Dzida, G. J., et al. (2024) · Current Topics in Diabetes · doi:10.5114/ctd/183052 · Cited by 33
Keegan, L. T., Truelove, S., & Lessler, J. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.40906 · Cited by 15
Mues, K. E., Kirk, B., Patel, D., Gelman, A., Chavers, L. S., Talarico, C. A., Esposito, D. B., Martin, D., Mansi, J. A., Chen, X., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.025 · Cited by 16
Κοντοπούλου, Κ., Ainatzoglou, A., Ifantidou, A. M., Nakas, C. T., Gkounti, G., Adamopoulos, V., Papadopoulos, N., & Papazisis, G. (2021) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001387 · Cited by 15
Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
Ambrosino, D. M., Han, H. H., Hu, B. T., Liang, J. G., Clemens, R. L., Johnson, M., Siber, G. R., & Goldblatt, D. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab574 · Cited by 16
The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines
Harris, J. E. (2022) · Health Policy and Technology · doi:10.1016/j.hlpt.2022.100619 · Cited by 18
Impact of Sex and Age on mRNA COVID-19 Vaccine-Related Side Effects in Japan
Mori, M., Yokoyama, A., Shichida, A., Sasuga, K., Maekawa, T., & Moriyama, T. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01309-22 · Cited by 20
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccinePreprint
Dayan, G. H., Rouphael, N., Walsh, S. R., Chen, A.-Y., Grunenberg, N., Allen, M., Antony, J., Asante, K., Bhate, A., Beresnev, T. H., et al. (2022) · medRxiv · doi:10.1101/2022.12.05.22282933 · Cited by 13
“The epidemiological context for this efficacy trial is markedly different from those conducted at the 299 pandemic’s onset.(18,19) A large proportion of participants had serological evidence of previous 300 infection representative of the epidemiological situation at the time of the study.”
ResultVisser, C., Biedermann, J. S., Nierman, M. C., van der Meer, F. J. M., Gulpen, A. J. W., Moors, Y. C. F., Cannegieter, S. C., Lijfering, W. M., Kruip, M. J. H. A., & Coalition, O. B. O. T. D. C. &. T. (2022) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1742628 · Cited by 15
Advanced Molecular Tweezers with Lipid Anchors against SARS-CoV-2 and Other Respiratory Viruses
Weil, T., Kirupakaran, A., Le, M., Rebmann, P., Mieres‐Pérez, J., Issmail, L., Conzelmann, C., Müller, J. A., Rauch‐Wirth, L., Gilg, A., et al. (2022) · JACS Au · doi:10.1021/jacsau.2c00220 · Cited by 17
Williamson, S., Dennison, L., Greenwell, K., Denison‐Day, J., Mowbray, F., Richards-Hall, S., Smith, D., Bradbury, K. J., Ainsworth, B., Little, P. S., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-059661 · Cited by 19
Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domainPreprint
Kobiyama, K., Imai, M., Jounai, N., Nakayama, M., Hioki, K., Iwatsuki‐Horimoto, K., Yamayoshi, S., Tsuchida, J., Niwa, T., Suzuki, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.04.433852 · Cited by 15
Yong, S. J., Halim, A., Halim, M., Mutair, A. S. A., Alhumaid, S., AlSihati, J., Albayat, H., Alsaeed, M., Garout, M. A., Azmi, R. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10071067 · Cited by 16
Na, Y. S., Kim, J. H., Baek, M. S., Kim, W., Baek, A.-R., Lee, B. Y., Seong, G. M., & Lee, S. (2022) · Acute and Critical Care · doi:10.4266/acc.2022.00017 · Cited by 16
“Vaccination is currently being implemented worldwide to prevent COVID-19 [2-4]; however, vaccination has not completely prevented COVID-19 [5].”
BackgroundCross-reactive antibodies after SARS-CoV-2 infection and vaccination
(2021) · doi:10.1101/2021.05.26.21256092 · Cited by 15
“Following the rapid initiation of many COVID- 19 vaccine studies, the first vaccines are already FDA/EMA approved and mass vaccination campaigns are rolled out to hopefully soon subdue this pandemic (Polack et al., 2020; Baden et al., 2021; Voysey et al., 2021; Sadoff et al., 2021).”
BackgroundMarrone, G., Covino, M., Merra, G., Piccioni, A., Amodeo, A., Novelli, A., Murri, R., Pompili, M., Gasbarrini, A., & Franceschi, F. (2023) · Liver International · doi:10.1111/liv.15736 · Cited by 14
Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis
Anand, S., Montez‐Rath, M. E., Han, J., García, P., Cadden, L., Hunsader, P., KERSCHMANN, R. L., Beyer, P., Boyd, S. D., Chertow, G. M., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0256 · Cited by 15
RNA interference therapeutics for cardiac regeneration
Huntington, J., Pachauri, M., Ali, H., & Giacca, M. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2021.05.007 · Cited by 18
CENTRAL RETINAL VEIN OCCLUSION FOLLOWING BNT162B2 (PFIZER-BIONTECH) COVID-19 MESSENGER RNA VACCINE
Shah, P. P., Gelnick, S., Jonisch, J., & Verma, R. (2021) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000001214 · Cited by 25
Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine
Fonseca, M. H. G., Pinto, A. C. M. D., Silva, M. F. S., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2806.220061 · Cited by 15
Cerebral venous thrombosis: a practical review
Borhani‐Haghighi, A., & Hooshmandi, E. (2023) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad103 · Cited by 15
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.